A newly published article in JAMA Oncology has reported hypothetical costs savings to Medicare of $320 million over a 3-year time frame if men of > 70 years with low-risk prostate cancer are simply “observed” as opposed being given immediate treated. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: conservative, cost, Management, Medicare, observation, saving | Leave a comment »
Slowly but perhaps inexorably we seem to be seeing increasing scientific and clinical justification for the argument that all men thought to be at risk for a diagnosis of prostate cancer should be given an MRI scan prior to any form of prostate biopsy. … READ MORE …
Filed under: Diagnosis | Tagged: biopsy, cost, efficiency, MRI, standard | 8 Comments »
A recent report in Urology Practice makes what we see as a somewhat odd statement about what patients may be willing to pay for an MRI/TRUS fusion-guided biopsy as opposed to a TRUS-guided prostate biopsy. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: biopsy, cost, fusion, MRI | 4 Comments »
On Wednesday the U.S. Patent Trial and Appeal Board invalidated the last remaining patent on abiraterone acetate (Zytiga), making it possible that generic forms of abiraterone acetate would be available in 2018 (at least in the US). … READ MORE …
Filed under: Uncategorized | Tagged: abiraterone, cost, generic, patent, Zytiga | Leave a comment »
As regular readers will be well aware, there are now several different tests available that can be used to assess risk for low- and very low-risk forms of prostate cancer at time of diagnosis (as opposed to clinically significant forms that need early treatment). … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment, Uncategorized | Tagged: cost, genetic, genomic, Management, risk, test | 4 Comments »
According to a story on the MarketWatch web site yesterday, two not-for-profit organizations have been seeking hearings on revocation of patents held by Medivation on the drug enzalutamide (Xtandi). … READ MORE …
Filed under: Uncategorized | Tagged: cost, enzalutamide, hearing, price, Xtandi | 11 Comments »
The prostate cancer patient community should be aware of an “op-ed” in today’s New York Times by Drs. Gilbert Welch and Peter Albertsen arguing that Medicare should continue to let individual physicians make their own decisions about the use of the PSA test for risk of prostate cancer. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: cost, decision, Medicare, PSA, risk, screening, testing | 16 Comments »
In an article in the October 25 issue of The ASCO Post, Dr. Jonas de Souza of the University of Chicago has introduced a new initiative to help all cancer patients and their doctors address the increasing problems associated with the costs of cancer care. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: action, cancer, care, cost, financial, research, toxicity | Leave a comment »
In a new article in the journal Cancer, a research group associated primarily with the University of California, Los Angeles, have provided detailed information on the costs of first-line management of low-risk prostate cancer. … READ MORE …
Filed under: Diagnosis, Management, Treatment | Tagged: cost, low risk, Management, Treatment | 9 Comments »
In an article published on Monday September 28, in Pharmaceutical Executive (a well-known biopharmaceutical industry trade journal) a senior health care public relations executive recently laid out a detailed rationale for why the industry needs to do a better job … READ MORE …
Filed under: Living with Prostate Cancer | Tagged: access, cost, drug, life, price, survival, value | 5 Comments »
An article in the August 10 issue of The ASCO Post has recently asked the question, “Is proton-beam therapy facing a difficult future?” … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cost, outcome, PBRT, proton | 5 Comments »
According to an announcement this morning from The Mayo Clinic, a group of 118 leading cancer experts has drafted proposals for reducing the high cost of cancer drugs and voiced support for a patient-based grassroots movement demanding action on the issue. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: advocacy, cost, drug, price | 5 Comments »
Yesterday the American Society of Clinical Oncology (ASCO) issued the initial draft of “a conceptual framework for assessing the value of new cancer therapies based on treatment benefits, toxicities, and costs.” ASCO is interested in getting feedback from its members and from the patient community too. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: benefit, cost, drug, Treatment, value | 5 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 